Jorveza

Budesonide, the active ingredient in Jorveza, is a glucocorticoid presented as an oral suspension for oral use. It acts as an anti‑inflammatory and immunosuppressant, and is approved in the European Union for the management of Crohn’s disease in adult patients.

GNH USA supplies Jorveza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑approved therapy. All batches are manufactured under GMP standards and undergo rigorous quality testing before distribution, ensuring consistency and safety for patients.

Budesonide in Jorveza is used to treat inflammatory bowel disease, specifically Crohn’s disease, by reducing intestinal inflammation.

- Crohn's disease: reduces intestinal inflammation and helps induce and maintain remission in adult patients.

Budesonide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth. - Nausea: feeling of sickness or upset stomach. - Headache: mild to moderate head pain. - Abdominal pain: discomfort in the stomach area. - Dyspepsia: indigestion or heartburn. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Severe infection: increased susceptibility to bacterial, viral, or fungal infections. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Osteoporosis: loss of bone density with long‑term use. - Growth retardation: impaired growth in pediatric patients. - Thromboembolic events: rare blood clot formation.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications.

- Assess infection risk: screen for active infections before starting treatment. - Monitor adrenal function: watch for signs of adrenal insufficiency, especially with abrupt discontinuation. - Use lowest effective dose: aim to minimise systemic exposure. - Avoid abrupt withdrawal: taper the dose when discontinuing long‑term therapy. - Caution in hepatic impairment: adjust therapy as needed for liver dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Budesonide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Concomitant systemic glucocorticoids: risk of additive corticosteroid effects. - Live vaccines: reduced vaccine efficacy and potential infection.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels. - Diuretics: may enhance hypokalaemia. - NSAIDs: increase risk of gastrointestinal ulceration.